Removes extraneous word "maker" in first bullet
** J.P. Morgan raises PT on drugmaker Pacira Biosciences PCRX.O to $21 from $11
** New PT represents a 20.6% downside to the stocks's last close
** Says it maintains its "underweight" rating, increasing its PT "primarily reflecting later generic entry"
** Brokerage says co's current share price of ~$26 implies that the market is assuming generic entry for co's pain management drug, Exparel in 2035+, which it considers a "highly optimistic scenario" for PCRX and underestimates "competitive risk"
** Says "assume a more balanced outcome with market entry late this decade"
** Co's lead drug Exparel is a pain-management drug used after surgery
** Stock has fallen 11.4% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.